Ascend Biopharmaceuticals Ltd.
- Country
- 🇦🇺Australia
- Ownership
- Holding
- Established
- 2003-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor
- Conditions
- Basal Cell Nevus SyndromeBasal Cell Carcinoma
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Ascend Biopharmaceuticals Ltd
- Target Recruit Count
- 21
- Registration Number
- NCT04416516
- Locations
- 🇦🇺
Central Brisbane Dermatology, Brisbane, Queensland, Australia
🇦🇺Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇦🇺Veracity Clinical Research, Brisbane, Queensland, Australia
Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
- Conditions
- Basal Cell Carcinoma in Basal Cell Nevus Syndrome
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Ascend Biopharmaceuticals Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT03208296
- Locations
- 🇺🇸
OHSU, Portland, Oregon, United States
A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma
- Conditions
- Skin NeoplasmNodular Basal Cell Carcinoma of SkinBasal Cell Nevus Syndrome
- Interventions
- Biological: ASN-002
- First Posted Date
- 2015-09-15
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Ascend Biopharmaceuticals Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT02550678
- Locations
- 🇦🇺
St George Dermatology and Skin Cancer Centre, Kogarah, New South Wales, Australia
🇦🇺Siller Medical T/A Central Brisbane Dermatology, Brisbane, Queensland, Australia
🇦🇺Veracity Clinical Research, Brisbane, Queensland, Australia